Loading company
Beam Therapeutics Inc.
BEAM · Nasdaq · ·
Next earnings: November 3, 2026
$24.51+1.1%Sep 29 close
- 1M
- -15.5%
- 6M
- +1.2%
- 1Y
- +1.6%
- 5Y
- -74.2%
BEAM · Nasdaq · ·
Next earnings: November 3, 2026
$24.51+1.1%Sep 29 close
Beam Therapeutics Inc. is scheduled to report next on November 3, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $490K | $8.5M | -94.21% |
| Profit | -$122.7M | -$102.1M | -20.11% |
| Profit per share | -$1.18 | -$1.00 | -18.00% |
| Free Cash Flow | -$68.5M | -$79.6M | +13.92% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
“The second quarter marked another period of rapid progress and disciplined execution on the clinical, regulatory and operational milestones we set for Beam,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
Beam Therapeutics (Nasdaq: BEAM) is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. To achieve this vision, Beam has assembled a platform with integrated gene editing, delivery and internal manufacturing capabilities. Beam’s suite of gene editing technologies is anchored by base editing, a proprietary technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the DNA. This has the potential to enable a wide range of therapeutic editing strategies that Beam is using to advance a diversified portfolio of base editing programs. Beam is a values-driven organization committed to its people, cutting-edge science, and a vision of providing lifelong cures to patients suffering from serious diseases.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Beam Therapeutics Inc.’s Item 2.02 8-K filed August 4, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Beam Therapeutics Inc. has no earnings call transcript available.